Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

PRNewsWire • Oct 7, 2026

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Oct 5, 2026

Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.

MarketBeat • Oct 2, 2026

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.

24/7 Wall Street • Sep 30, 2026

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

Zacks Investment Research • Sep 29, 2026

Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial

Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.

Barrons • Sep 28, 2026

Why Kodiak Sciences Skyrocketed Today

Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.

The Motley Fool • Sep 29, 2026

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.

Proactive Investors • Sep 28, 2026

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Seeking Alpha • Sep 28, 2026

Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.

Investors Business Daily • Sep 28, 2026